Codex DNA, Inc. (DNAY): Price and Financial Metrics
DNAY Price/Volume Stats
|Current price||$1.30||52-week high||$11.02|
|Prev. close||$1.20||52-week low||$1.08|
|Day high||$1.31||Avg. volume||0|
|50-day MA||$1.44||Dividend yield||N/A|
|200-day MA||$2.61||Market Cap||38.38M|
DNAY Stock Price Chart Interactive Chart >
Codex DNA, Inc. (DNAY) Company Bio
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Most Popular Stories View All
DNAY Latest News Stream
|Loading, please wait...|
DNAY Latest Social Stream
View Full DNAY Social Stream
Latest DNAY News From Around the Web
Below are the latest news stories about TELESIS BIO INC that investors may wish to consider to help them evaluate DNAY as an investment opportunity.
Telesis Bio, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Telesis Bio, Inc. ( NASDAQ:DNAY ) just kicked off its latest third-quarter results with some very...
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates
Codex DNA (DNAY) delivered earnings and revenue surprises of 12.50% and 25.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Telesis Bio Inc. Reports Third Quarter 2022 Financial Results
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022.
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
Agreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNASAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and validation of Telesis Bio’s BioXp® Digital-to-Biological Converter™ (DBC) instrument for full
DNAY Price Returns
Loading social stream, please wait...